Last updated: 2026-10-13 07:28:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ardelyx, Inc. (ARDX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3,23, with a market capitalisation of $846,86M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,18 to $8,40. This page covers its latest market performance, valuation, price trends and company information.
$846,86M | |
$3,28 | |
$35,48 | |
$0,49 | |
$3,28 | |
2,93M | |
4,20M | |
-- | |
$8,40 | |
$3,18 | |
-- | |
-- |
Ardelyx, Inc. (ARDX) last closed at $3,28 as of 2026-10-12 23:45:00, unchanged from the previous close of $3,28.
During the latest regular trading session, ARDX traded between $0,49 and $35,48, with a volume of 2,93M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Ardelyx, Inc. (ARDX) moved from $3,34 to $3,23, representing a decline of 3,44% ($0,11).
The stock traded between $3,18 and $3,42 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 4,57 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0,9%
ARDX is currently trading at $3,23, placing it 0,9% of the way from its 52-week low of $3,18 to its 52-week high of $8,40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 489 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ardelyx, Inc. (ARDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.